NCT00179127

Use of Insulin Glargine to Treat Diabetic Ketoacidosis

Early Use of Insulin Glargine in Diabetic Ketoacidosis

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 75 (actual)
• Sponsor: Vanderbilt University Medical Center · Academic / Other
• Sex: All
• Age: 6 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effects of the addition of insulin glargine during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children. The investigators hypothesize that the addition of insulin glargine during the early phase of management of DKA will accelerate acidosis correction, decrease the length of insulin infusion, and decrease the total intensive care unit time in children admitted to the ICU.

Conditions

• Diabetic Ketoacidosis

Interventions

Type	Name	Description
DRUG	glargine	0.3u/kg of glargine, subcutaneously, once
DRUG	saline	0.3u/kg of saline, subcutaneously, once

Timeline

• Start date: 2004-08-01
• Primary completion: 2009-07-01
• Completion: 2012-09-01
• First posted: 2005-09-15
• Last updated: 2018-07-16
• Results posted: 2018-07-16

Locations

1 site across 1 country: United States